Levosimendan in acute decompensated heart failure: Systematic review and meta-analysis;Levosimendan na insuficiência cardíaca descompensada: Revisão sistemática e metanálise

Arquivos Brasileiros de Cardiologia

Volumn 95, Issue 2, 2010, Pages 230-237

  Ribeiro, Rodrigo Antonini ^a   Rohde, Luis Eduardo Paim ^a,b,c   Polanczyk, Carisi Anne ^a,b,c  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c Instituto Nacional de Ciencia e Tecnologia para Avaliacao de Tecnologias em Saude (IATS) CNPq   (Brazil)

Author keywords

Drugs; Heart failure; Investigational; Levosimendan; Meta analysis

Indexed keywords

DOBUTAMINE; LEVOSIMENDAN; PLACEBO;

ACUTE HEART FAILURE; ARTICLE; CAUSE OF DEATH; CLINICAL TRIAL; DRUG COST; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HOSPITAL READMISSION; HUMAN; HYPOTENSION; LENGTH OF STAY; LOADING DRUG DOSE; MAINTENANCE THERAPY; META ANALYSIS; MORBIDITY; MORTALITY; RISK REDUCTION; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

BRAZIL; HEART FAILURE; HOSPITALIZATION; HUMANS; HYDRAZONES; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 77957292135     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2010005000072     Document Type: Article

References (32)

1. Ministério da Saúde. DATASUS. [Acessado em 02/05/2007]. Disponível em: http://w3.datasus.gov.br/datasus/datasus.php.
2. Bocchi EA, Vilas-Boas F, Perrone S, Caamano AG, Clausell N, Moreira M da C, et al. I Latin American guidelines for the assessment and management of decompensated heart failure. Arq Bras Cardiol. 2005; 85 (Suppl 3): 49-94; 1-48.
3. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002; 287 (12): 1541-7.
4. Bayram M, De Luca L, Massie MB, Gheorghiade M. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol. 2005; 96 (6A): 47G-58G. (Pubitemid 41338074)
5. Innes CA, Wagstaff AJ. Levosimendan: a review of its use in the management of acute decompensated heart failure. Drugs. 2003; 63 (23): 2651-71.
6. Earl GL, Fitzpatrick JT. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure. Ann Pharmacother. 2005; 39 (11): 1888-96.
7. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol. 2002; 31 (1): 150-3.
8. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003; 327 (7414): 557-60.
9. Delaney A, Bradford C, McCaffrey J, Bagshaw SM, Lee R. Levosimendan for the treatment of acute severe heart failure: a meta-analysis of randomised controlled trials. Int J Cardiol. 2008; 138 (3): 281-9..
10. Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med. 2005; 31 (5): 638-44.
11. Parissis JT, Panou F, Farmakis D, Adamopoulos S, Filippatos G, Paraskevaidis I, et al. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol. 2005; 96 (3): 423-6.
12. Berger R, Moertl D, Huelsmann M, Bojic A, Ahmadi R, Heissenberger I, et al. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure. Eur J Heart Fail. 2007; 9 (2): 202-8. (Pubitemid 46394079)
13. Fuhrmann JT, Schmeisser A, Schulze MR, Wunderlich C, Schoen SP, Rauwolf T, et al. Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med. 2008; 36 (8): 2257-66.
14. Parissis JT, Papadopoulos C, Nikolaou M, Bistola V, Farmakis D, Paraskevaidis I, et al. Effects of levosimendan on quality of life and emotional stress in advanced heart failure patients. Cardiovasc Drugs Ther. 2007; 21 (4): 263-8.
15. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002; 360 (9328): 196-202.
16. Yilmaz MB, Yontar C, Erdem A, Karadas F, Yalta K, Turgut OO, et al. Comparative effects of levosimendan and dobutamine on right ventricular function in patients with biventricular heart failure. Heart Vessels. 2009; 24 (1): 16-21.
17. Bocchi EA, Vilas-Boas F, Moreira MC, Barretto AC, Lage S, Albuquerque D, et al. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study. Arq Bras Cardiol. 2008; 90 (3): 182-90.
18. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006; 27 (22): 2725-36.
19. Oliveira MT Jr, Follador W, Martins ML, Canaviera R, Tsuji RL, Scipioni A, et al. Cost analysis of the treatment of acute decompensated heart failure. Levosimendan versus dobutamine. Arq Bras Cardiol. 2005; 85 (1): 9-14.
20. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail. 2006; 8 (1): 105-10.
21. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol. 2000; 36 (6): 1903-12.
22. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, et al. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction: a randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002; 23 (18): 1422-32.
23. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation. 2003; 107 (1): 81-6. (Pubitemid 36070937)
24. Cleland JG, Ghosh J, Freemantle N, Kaye GC, Nasir M, Clark AL, et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUSUS, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur J Heart Fail. 2004; 6 (4): 501-8.
25. Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol. 2006; 98 (1): 102-6.
26. Flevari P, Parissis JT, Leftheriotis D, Panou F, Kourea K, Kremastinos DT. Effect of levosimendan on ventricular arrhythmias and prognostic autonomic indexes in patients with decompensated advanced heart failure secondary to ischemic or dilated cardiomyopathy. Am J Cardiol. 2006; 98 (12): 1641-5.
27. Follath F, Hinkka S, Jäger D, Just H, Mitrovic V, Papp J, et al. Dose-ranging and safety with intravenous levosimendan in low-output heart failure: experience in three pilot studies and outline of the levosimendan infusion versus dobutamine (LIDO) trial. Am J Cardiol. 1999; 83 (12B): 16(I)-20(I).
28. Alvarez J, Bouzada M, Fernandez AL, Caruezo V, Taboada M, Rodriguez J, et al. Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery. Rev Esp Cardiol. 2006; 59 (4): 338-45.
29. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007; 297 (17): 1883-91.
30. Samimi-Fard S, Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Abreu- Gonzalez P. Effects of levosimendan versus dobutamine on long-term survival of patients with cardiogenic shock after primary coronary angioplasty. Int J Cardiol. 2008; 127 (2): 284-7.
31. Duygu H, Nalbantgil S, Ozerkan F, Zoghi M, Akilli A, Erturk U, et al. Effects of levosimendan on left atrial functions in patients with ischemic heart failure. Clin Cardiol. 2008; 31 (12): 607-13.
32. Duygu H, Turk U, Ozdogan O, Akyuz S, Kirilmaz B, Alioglu E, et al. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol. Cardiovasc Ther. 2008; 26 (3): 182-8.